Praxis Precision Medicines (NASDAQ:PRAX – Get Rating)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $16.00 price target on the stock. Separately, William Blair downgraded shares of Praxis Precision Medicines from an “outperform” rating to a “market perform” rating in a […]